DCF Advisers LLC bought a new position in Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 38,000 shares of the company’s stock, valued at approximately $698,000.
A number of other large investors have also made changes to their positions in the company. Perceptive Advisors LLC boosted its stake in Viridian Therapeutics by 108.1% in the 4th quarter. Perceptive Advisors LLC now owns 3,042,703 shares of the company’s stock worth $94,689,000 after purchasing an additional 1,580,303 shares during the period. Morgan Stanley lifted its holdings in shares of Viridian Therapeutics by 805.6% in the fourth quarter. Morgan Stanley now owns 1,738,225 shares of the company’s stock valued at $54,094,000 after purchasing an additional 1,546,284 shares in the last quarter. Avoro Capital Advisors LLC acquired a new stake in shares of Viridian Therapeutics in the fourth quarter worth $46,680,000. Vanguard Group Inc. boosted its position in shares of Viridian Therapeutics by 29.6% in the fourth quarter. Vanguard Group Inc. now owns 5,612,144 shares of the company’s stock worth $174,650,000 after buying an additional 1,280,161 shares during the period. Finally, Commodore Capital LP grew its holdings in shares of Viridian Therapeutics by 35.4% during the second quarter. Commodore Capital LP now owns 4,875,000 shares of the company’s stock valued at $68,152,000 after buying an additional 1,275,000 shares in the last quarter.
Analyst Ratings Changes
Several equities research analysts recently issued reports on the company. Truist Financial increased their price objective on Viridian Therapeutics from $38.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Stifel Nicolaus set a $39.00 target price on Viridian Therapeutics in a research note on Wednesday, May 13th. Royal Bank Of Canada upped their target price on Viridian Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a report on Friday, August 7th. Evercore set a $26.00 price target on shares of Viridian Therapeutics in a research report on Friday, May 15th. Finally, Needham & Company LLC restated a “buy” rating and set a $32.00 price target on shares of Viridian Therapeutics in a report on Monday, June 29th. Thirteen analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $38.93.
Viridian Therapeutics Price Performance
NASDAQ VRDN opened at $24.80 on Thursday. Viridian Therapeutics, Inc. has a fifty-two week low of $13.18 and a fifty-two week high of $34.29. The stock’s 50-day moving average is $19.49 and its two-hundred day moving average is $21.03. The firm has a market cap of $2.81 billion, a P/E ratio of -7.36 and a beta of 0.91. The company has a debt-to-equity ratio of 0.43, a current ratio of 16.95 and a quick ratio of 16.95.
Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by ($0.02). The company had revenue of $0.28 million for the quarter, compared to the consensus estimate of $0.06 million. Viridian Therapeutics had a negative return on equity of 72.97% and a negative net margin of 505.86%. On average, analysts anticipate that Viridian Therapeutics, Inc. will post -4.07 earnings per share for the current fiscal year.
About Viridian Therapeutics
Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.
In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.
Featured Articles
- Five stocks we like better than Viridian Therapeutics
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
